E

Enanta Pharmaceuticals

ENTA

14.800
USD
0.04
(0.27%)
Market Closed
Volume
2,277
EPS
0
Div Yield
0
P/E
-2
Market Cap
232,226,738
Related Instruments
AMGN
2.78
(0.84%)
335.22 USD
GILD
0.470
(0.62%)
76.510 USD
I
INCY
-0.680
(-1.05%)
64.390 USD
I
ITCI
0.260
(0.33%)
79.030 USD
K
KPTI
-0.06290
(-6.37%)
0.92380 USD
News

Title: Enanta Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.